DENVER, Nov. 1 /PRNewswire-FirstCall/ -- Global Med Technologies(R), Inc. (OTC Bulletin Board: GLOB), an international e-Health, medical information technology company, will be presenting at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference to be held November 5-7 at the New York Palace Hotel in New York City.
On Tuesday, November 6th, at 11:15 a.m. EST, Dr. Michael Ruxin, Chief Executive Officer of Global Med Technologies, will give a 20-minute presentation in the Spellman Room, regarding Global Med's business and discuss its unique value proposition, latest developments, financial performance and prospects. Management will also participate in a question and answer session following the presentation and in one-on-one meetings throughout the day.
The Acumen Biofin Rodman & Renshaw Healthcare Conference will include presentations by over 350 companies, as well as experts from the medical, scientific and investment communities. The categories of presentation include autoimmune diseases, cardiovascular diseases, CNS, drug delivery, gene therapy, infectious diseases, medical devices, oncology, specialty pharmaceuticals, and therapeutic vaccines. A vast number of Investors, venture capitalists, company executives, scientists and other industry leaders are expected to attend.
About Global Med Technologies, Inc.
Global Med Technologies(R), Inc. is an international e-Health medical information technology company providing information management software products and services to the healthcare industry. Its Wyndgate Technologies(R) division is a leading supplier of information management systems to U.S. and international blood centers and hospital transfusion centers. Each year, Wyndgate's products and services manage more than eight million blood components, representing over 27% of the U.S. blood supply. Wyndgate's products are also being used in Canada and sub-Saharan Africa, and are being implemented in the Caribbean. Together, the Donor Doc(TM) interactive donor health history questionnaire, SafeTrace(R) donor management system, and the SafeTrace Tx(R) advanced transfusion management system, recently patented, provide Vein-to-Vein(R) tracking from donor collection to patient transfusion.
This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release.
|SOURCE Global Med Technologies, Inc.|
Copyright©2007 PR Newswire.
All rights reserved